By Manon C. Posted on January 11, 2022 at 11:54 a.m.
Pfizer announced this Monday, January 10, 2022, that its new version of the vaccine targeting more specifically the Omicron variant would be ready next March.
This is news that could, perhaps, convince the last refractory to vaccination who invoke, as a defense, the fact that current vaccines do not protect enough against the Omicron variant. the head of the Pfizer laboratory announced, this Monday, January 10, 2022, that its version of the vaccine adapted to the Omicron variant could be ready at next march, as he had already put forward at the end of last November.
“I don’t know if we will need it, I don’t know if or how it will be used, but we will be ready. The factory has already started production. We hope to be able to come up with a product that will protect much better against infections in particular, because the protection against hospitalizations and severe cases is quite reasonable with current vaccines if you have had the third dose. “ said Albert Bourla, the boss of the firm, on the American channel CNBC, announcing in addition that studies were going to be carried out in order to know if a fourth dose of vaccine is necessary.
For its part, the Managing Director of Moderna, Stéphane Bancel, indicated that the pharmaceutical company was currently working on a version of its vaccine specifically targeting Omicron. Entrant “soon” in clinical trial phase, this version of Moderna’s vaccine would be ready next fall.
“We are currently in discussions with health officials around the world to decide what we think is the best strategy for the potential recall for thefall 2022. We believe it will contain Omicron. We have to be careful to try to stay ahead of the virus, not stay behind. “ Stéphane Bancel clarified.
–
